Table 2.

Relationship of SPARC , VEGF expression, MVD and Ki-67 with clinicopathologic parameters

		SPARC			VEGF		MVD(\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline x \pm s $$\end{document})		Ki-67(\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline x \pm s $$\end{document})
parameters	n	high	low	P	(+) (−)	P		P		P
age
<50	12	7	5	0.531	10 2	0.175	45.33 ± 15.92	0.980	24.76 ± 8.30	0.446
≥50	68	33	35		43 25		45.23 ± 12.12		26.82 ± 8.64
gender
male	59	28	31	0.446	37 22	0.262	45.76 ± 12.44	0.547	27.49 ± 8.48	0.086
female	21	12	9		16 5		43.80 ± 13.42		23.75 ± 8.40
Laurentype
intestinal	38	24	14	0.025	18 20	0.001	38.71 ± 9.21	0.000	25.66 ± 8.90	0.402
diffuse	42	16	36		35 7		51.17 ± 12.50		27.28 ± 8.29
differentiation
high	41	28	13	0.001	21 20	0.004	39.29 ± 9.06	0.000	25.19 ± 8.01	0.157
low	39	12	27		32 7		51.51 ± 12.95		27.91 ± 9.01
stage
I–II	41	26	15	0.014	23 18	0.049	38.76 ± 7.05	0.000	23.86 ± 8.52	0.004
III–IV	39	14	25		30 9		52.08 ± 13.68		29.30 ± 7.79
Tumor
T4	50	24	26	0.644	35 15	0.360	48.98 ± 13.40	0.000	28.52 ± 7.77	0.001
T1-T3	30	16	14		18 12		39.03 ± 8.30		23.16 ± 8.91
LN
N1-N3	48	18	30	0.006	36 12	0.043	49.94 ± 13.70	0.000	28.49 ± 8.29	0.010
N0	32	22	10		17 15		38.22 ± 6.21		23.54 ± 8.23